WO1998047481A1 - Use of 5ht3 antagonists for promoting intestinal lavage - Google Patents

Use of 5ht3 antagonists for promoting intestinal lavage Download PDF

Info

Publication number
WO1998047481A1
WO1998047481A1 PCT/EP1998/002356 EP9802356W WO9847481A1 WO 1998047481 A1 WO1998047481 A1 WO 1998047481A1 EP 9802356 W EP9802356 W EP 9802356W WO 9847481 A1 WO9847481 A1 WO 9847481A1
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
laxative
combination
administration
antagonists
Prior art date
Application number
PCT/EP1998/002356
Other languages
French (fr)
Inventor
Antonius Adrianus Hendrikus Petrus Megens
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Priority to US09/403,248 priority Critical patent/US6235745B1/en
Priority to EP98922759A priority patent/EP0975327B1/en
Priority to KR10-1999-7007936A priority patent/KR100529512B1/en
Priority to JP54502298A priority patent/JP2001523239A/en
Priority to DE69816060T priority patent/DE69816060T2/en
Priority to DK98922759T priority patent/DK0975327T3/en
Priority to AU75282/98A priority patent/AU745361B2/en
Priority to CA002286076A priority patent/CA2286076C/en
Priority to AT98922759T priority patent/ATE243993T1/en
Publication of WO1998047481A1 publication Critical patent/WO1998047481A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is concerned with the use of 5HT 3 antagonists for accelerating intestinal lavage in combination with a laxative, in particular an osmotic agent.
  • the present invention is also concerned with the use of said 5HT3 antagonists in combination with a laxative for the treatment of constipation.
  • These agents may also be used to help eliminate parasites following appropriate therapy, for instance these can be used after or in combination with anthelmintics. These osmotic agents may also be used to help eliminate toxic material in some cases of poisoning.
  • 5HT3 receptors appear to mediate the excitatory actions of 5-HT (serotonin) in the peripheral nervous system.
  • the peripheral 5HT3 receptor plays a pivotal role in the process of emesis induced by cytotoxic chemotherapy and radiotherapy.
  • Peripheral 5HT3 antagonists are also being studied for the treatment of irritable bowel syndrome and visceral pain.
  • Evidence has accumulated showing the presence of 5HT3 receptors in the central nervous system.
  • Central 5HT3 receptors have been implicated in cognition and memory disorders, anxiety and dopamine modulation of the mesolimbic structures. Antagonists of the 5HT3 receptor have been proposed for treating these disorders.
  • 5HT3 receptor antagonists In animal models of anxiety, 5HT3 receptor antagonists have been shown to exert anxiolytic properties similar to those of benzodiazepines but without sedative, anticonvulsant and muscle relaxant actions.
  • Ondansetron hydrochloride launched in 1990 as an antiemetic, is being studied in clinical trials for the treatment of age-related cognition disorders and generalized anxiety. Recent studies have suggested an interrelation between the serotonergic and dopaminergic systems, especially through the 5HT3 receptor. 5HT3 antagonists may thus have potential as therapeutic agents for the treatment of hyperdopaminergic disease states such as schizophrenia, without presenting the side effects liability generally associated with classic neuroleptics. (Joseph R. Prous, "The Year's Drug News, Therapeutic Targets, 1994 Edition)
  • 5-HT3-receptor antagonists can be identified by the fact that they are active, for example, in antagonising the Von Bezold-Jarisch chemoreflex evoked by serotonin in rats (Pharmacology and Toxicology, 70, Supp II, 17-22 (1992)).
  • 5HT 3 receptor antagonists slow colonic transit and may even cause mild constipation.
  • 5HT 3 antagonists have a synergistic effect with osmotic agents to obtain intestinal lavage, i.e. an induced form of diarrhea which is quite the opposite of constipation.
  • 5HT3 antagonists are Azasetron HC1, Granisetron HC1, Ondansetron HC1, Tropisetron, DAT-582, Dolasetron mesylate, Itasetron, N-3389, Pancopride,
  • 5HT 3 antagonist is (-)-cis-4-amino-5-chloro-2,3-dihydro-N-[l- [3-[(3,4-dihydro-4-oxo-2-pyrimidinyl)amino]propyl]-3-methoxy-4-piperidinyl]-2,2-di- methyl-7-benzofurancarboxamide, which will be referred to hereinafter as "COMPOUND A”, which is described as compound number 1 of WO 94/12494, published 9 June 1994.
  • the pharmaceutically acceptable acid or base addition salt of the 5HT 3 antagonists are also intended to be included in the present invention.
  • the pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the 5HT 3 antagonists are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e.
  • ethanedioic malonic
  • succinic i.e. butanedioic acid
  • maleic fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
  • the 5HT3 antagonists containing an acidic proton may also be converted into their non- toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form.
  • solvates are for example hydrates, alcoholates and the like.
  • Laxatives are drugs that promote defecation. Precise mechanisms of action of many laxatives remain uncertain because of the complex factors that affect colonic function, prominent variations of water and electrolyte transport among experimental species and preparations, and a certain costiveness of research in this area. Three general mechanisms of laxative action can be described. (1) By their hydrophilic or osmotic properties, laxatives may cause retention of fluid in colonic contents, thereby increasing bulk and softness and facilitating transit. (2) Laxatives may act, both directly and indirectly, on the colonic mucosa to decrease net absorption of water and ⁇ aCl. (3) Laxatives may increase intestinal motility, causing decreased absorption of salt and water secondary to decreased transit time.
  • laxatives i.e. 1) dietary fiber and bulk-forming laxatives, 2) saline and osmotic laxatives and 3) stimulant laxatives, (see Goodman and Gilman, seventh edition, pp 994 to 1003).
  • the bulk-forming laxatives include a wide range of natural and semisynthetic polysaccharides and cellular derivatives that are only partially digested.
  • the undigested portions are hydrophilic and swell in the presence of water to form a viscous solution or gel.
  • the increased intraluminal pressure reflexively stimulates peristalsis, diminishes colonic transit time and produces a soft gelatinous stool (" Remington's Pharmaceutical Sciences", page 783 - 786, 1990, Mack Publishing Company, Easton, Pennsylvania, 18th edition).
  • the stimulant laxatives act on the intestinal tract to increase its motor activity.
  • the more commonly employed agents are the anthraquinone laxatives, such as, e.g. cascara sagrada and senna; the diphenylmethane derivatives, such as, e.g. phenolphtalein and bisacodyl; and castor oil ("Remington's Pharmaceutical Sciences", page 783 - 786, 1990, Mack Publishing Company, Easton, Pennsylvania, 18th edition).
  • Saline and osmotic laxatives are the primary class of laxatives envisaged in this invention.
  • Saline and osmotic laxatives include various magnesium salts; the sulfate, phosphate, and tartrate salts of sodium and potassium; the dissacharide lactulose; glycerin; and sorbitol. They are poorly and slowly absorbed and act by their osmotic properties in the luminal fluid.
  • KleanPrep ® and GoLytely ® Two examples of these osmotic agents which are commercially available for intestinal cleansing are KleanPrep ® and GoLytely ® .
  • the present invention is concerned with the use of a 5HT 3 antagonist for the manufacture of a medicament that will improve, accelerate or promote the intestinal cleansing by laxatives, in particular osmotic agents.
  • a method of treatment whereby an effective amount of a 5HT 3 antagonist is administered to a warm- blooded animal, in particular a mammal, in combination with a laxative, in particular an osmotic agent.
  • the patients envisaged in this treatment are people whose bowel needs to be cleaned prior to diagnostic or surgical procedures.
  • Another group of patients are those patients who are to be prevented from straining at the stool, these patients include people suffering from hernia or cardiovascular disease.
  • the combination of the present invention can be indicated, both before and after surgery, to maintain soft feces in patients with hemorrhoids and other anorectal disorders.
  • Osmotic agents at cathartic doses are frequently employed prior to radiological examination of the gastrointestinal tract, kidneys, or other abdominal or retroperitoneal structures and prior to elective bowel surgery. Hence, also for these applications the presently described combination may be useful.
  • combination of the present invention can also be used in the treatment of drug overdosage and poisoning, by removing agents from the intestine.
  • the combination of the present invention may also be employed in further combination with with certain anthelmintics.
  • the present invention provides a method to accelerate and/or enforce the action of laxatives, especially osmotic agents.
  • the laxatives can be administered or co-administered orally or rectally.
  • co-administration means that the laxative and the 5HT3 ⁇ antagonist are present in the gastro-intestinal tract during at least partially overlapping times. Additionally, “co-administration” comprehends administering more than one dose of said laxative within 1 hour after a dose of the 5HT3-antagonist, in other words, the 5HT 3 -antagonist need not be administered again before or with every administration of said laxative, but may be administered intermittently during the course of treatment.
  • the present invention is also concerned with the use of said 5HT 3 antagonists in combination with a laxative for the treatment of constipation, such as acute constipation, chronic constipation or refractory constipation. Consequently, a method is provided to treat constipation, such as, e.g. acute constipation, chronic constipation or refractory constipation, in warm-blooded animals, in particular mammals, by administration of a laxative in combination with an effective amount of a 5HT3 antagonist.
  • constipation such as, e.g. acute constipation, chronic constipation or refractory constipation
  • the 5HT3-antagonists may be formulated into various pharmaceutical forms for administration purposes.
  • an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is intimately mixed with a pharmaceutically acceptable carrier.
  • Said carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are _ obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on. as an ointment.
  • Dosage unit form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • the dosages of the drugs used in the present invention must, in the final analysis, be set by the physician in charge of the case, using knowledge of the drugs, the properties of the drugs in combination as determined in clinical trials, and the characteristics of the patient, including diseases other than that for which the physician is treating the patient.
  • an effective amount of a 5HT3 antagonist would be from about 0.001 mg kg to about 50 mg/kg body weight, preferably from about 0.02 mg/kg to about 5 mg/kg body weight.
  • a method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.
  • this invention provides a therapeutic package suitable for commercial sale, comprising a container, an dosage form of a 5HT3 antagonist and a laxative, in particular an osmotic agent.
  • This laxative or osmotic agent is often in the form of a powder, which is normally to be dissolved or suspended in a certain amount of water. Consequently, the present invention also relates to a product comprising a 5HT 3 antagonist and a laxative, in particular an osmotic agent, for simultaneous, separate or sequential use in the treatment of constipation or for promoting intestinal lavage, provided that said product does not contain an opioid antagonist.
  • Such a product may comprise a kit comprising a container containing a pharmaceutical composition of a laxative, and another container comprising a pharmaceutical composition of the 5HT 3 antagonist.
  • the product with separate compositions of the laxative and the 5HT 3 antagonist has the advantage that appropriate amounts of each component, and timing and sequence of administration can be selected in function of the patient.
  • WO-96/14071 published on 17 May 1996, discloses combinations consisting of laxatives, ⁇ -adrenergic agents, antiemetic agents, gastric protectors, optionally proton pump inhibitors, anxiolytic compounds, an anesthetic sleep-inducing agent, and an opioid antagonist, such as nalaxone or naltrexone; intended to suppress dependence on opioids.
  • Labelled membranes were collected and raised by rapid- filtration under suction over Walkman GF B plan fibre filters (presoaked in 0.1 % polyethyleneimine for at least 1 hour) using a 40-well filtration manifold. Test compounds were added at appropriate concentrations (60 minutes incubation time), in such a way that the inhibition curves were defined by at least eight to twelve concentration points, measured in duplicate. All experiments were repeated independently at least two times. Radioactivity on the filters was counted in a Packard Tri-carb 1600CA liquid scintillation analyzer. Counting data were collected directly in a Macintosh SE personal computer and further transferred to a Macintosh II personal computer.
  • Counting data from assays in the presence of a compound were automatically expressed as percent of total binding measured in the absence of test compound. Inhibition curves plotting percent of total binding versus the log concentrations of the test compound were automatically generated.
  • the sigmoidal inhibition curves were analyzed by computerized curve-fitting, with a programme using non-linear regression analysis for one- or two site curve fitting (modifications of equations described in Oestreicher E.G. and Pinto G.F., Comput. Biol. Med., 17, 53-68 (1987).
  • the -log IC 5 o values (PIC50', IC50 defined as the concentration producing 50% inhibition of specific radioligand binding) were derived from individual curves.
  • the K j values of the test compounds are presented as logarithmic mean and corresponding 95% confidence limits of the various determinations; and are presented in Table 1 in the column labelled "5HT 3 receptor K; (95% c.l.) nM".
  • Beagle dogs (of both sexes and varying in body weight, 16 hours deprived from food) were orally pretreated with the test compound (0.5 ml/kg) and challenged 1 hour later with an oral administration of magnesium sulphate (MgSO 7H 2 ⁇ , 64g/l, 0.26M; 200 ml).
  • MgSO 7H 2 ⁇ , 64g/l, 0.26M; 200 ml magnesium sulphate
  • the onset of MgSO4-induced intestinal lavage was assessed over a period of 4 hours after challenge. Liquid stools within 4 hours occured almost never in control animals treated with distilled water (3.0% false positives; n>100) and were considered to reflect significant acceleration of the MgSOAnduced intestinal lavage.
  • Doses in the active dose range were given to five animals each, tested in separate experimental sessions including solvent-treated control animals.
  • test compounds were obtained from the companies of origin : bemesetron, BIMU-8, DAU-6236, granisetron, ondansetron, tropisetron, YM-060, renzapride and zacopride, as well as Compound A.
  • test compounds have been listed in Table 1. All compounds showed affinity for the 5HT3 receptor, inhibited 5-hydroxykynuramine (5-OH-K)-induced contractions of the guinea-pig ileum, antagonized the Von Bezold Jarisch reflex and stimulated gastric emptying in rats, and the accelerated appearance of MgSO4-induced loose stools in dogs.
  • 5-OH-K 5-hydroxykynuramine
  • Table 1 Binding to the serotonin 5HT 3 receptor (Kj, nM); and acceleration of MgSO 4 induced diarrhea in dogs (ED5 0 , ⁇ g/kg, po).
  • the dogs were orally pretreated with test compound or distilled water (0.5 ml/kg) and 1 hour later challenged by gavage with KleanPrep ® solution.
  • the KleanPrep ® solution was administered more than once at 15 minutes intervals.
  • the standard administration volume was 200 ml. The occurrence of liquid stools at 1, 2, 3, 4, 5 and 6 hours after the first administration of KleanPrep ® was noted.
  • the KleanPrep ® solution consisted of polyethyleneglycol 3350 (59 g/1), sodium sulfate (5.685 g/1), sodium hydrogencarbonate (1.685 g/1), sodium chloride (1.465 g/1), potassium chloride (0.7425 g/1), aspartate (0.0494 g/1) and vanille (0.3291 g/1).
  • Two dogs produced the first liquid stool after the 7th administration of KleanPrep ® (corresponding to a total volume of 1400 ml; the first liquid stool at 95 and 101 min).

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention is concerned with the use of 5HT3 antagonists for promoting intestinal lavage, especially in combination with an osmotic agent.

Description

USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE
The present invention is concerned with the use of 5HT3 antagonists for accelerating intestinal lavage in combination with a laxative, in particular an osmotic agent. The present invention is also concerned with the use of said 5HT3 antagonists in combination with a laxative for the treatment of constipation.
Intestinal lavage
Adequate colon preparation before diagnostic, therapeutic or surgical procedures is important because safety and diagnostic accuracy depend on adequate cleansing of the intestines. Magnesium sulfate (MgSO_ or, more recently, polyethylene glycol (PEG)-electrolyte solutions (e.g., KleanPrep® or GoLytely®) have been widely used as lavage solution for colon preparation. These solutions, generally well tolerated by patients, are extremely effective in cleansing the colonic mucosa of faeculent debris. However, fairly large volumes (4 liters) and relatively long preparation times (up to 24 hours) are required. Reduction of the volume to be ingested and shortening of the preparation time would highly increase patient acceptance and comfort.
These agents may also be used to help eliminate parasites following appropriate therapy, for instance these can be used after or in combination with anthelmintics. These osmotic agents may also be used to help eliminate toxic material in some cases of poisoning.
5HT3 antagonists
5HT3 receptors appear to mediate the excitatory actions of 5-HT (serotonin) in the peripheral nervous system. The peripheral 5HT3 receptor plays a pivotal role in the process of emesis induced by cytotoxic chemotherapy and radiotherapy. Peripheral 5HT3 antagonists are also being studied for the treatment of irritable bowel syndrome and visceral pain. Evidence has accumulated showing the presence of 5HT3 receptors in the central nervous system. Central 5HT3 receptors have been implicated in cognition and memory disorders, anxiety and dopamine modulation of the mesolimbic structures. Antagonists of the 5HT3 receptor have been proposed for treating these disorders. In animal models of anxiety, 5HT3 receptor antagonists have been shown to exert anxiolytic properties similar to those of benzodiazepines but without sedative, anticonvulsant and muscle relaxant actions. Ondansetron hydrochloride, launched in 1990 as an antiemetic, is being studied in clinical trials for the treatment of age-related cognition disorders and generalized anxiety. Recent studies have suggested an interrelation between the serotonergic and dopaminergic systems, especially through the 5HT3 receptor. 5HT3 antagonists may thus have potential as therapeutic agents for the treatment of hyperdopaminergic disease states such as schizophrenia, without presenting the side effects liability generally associated with classic neuroleptics. (Joseph R. Prous, "The Year's Drug News, Therapeutic Targets, 1994 Edition)
5-HT3-receptor antagonists can be identified by the fact that they are active, for example, in antagonising the Von Bezold-Jarisch chemoreflex evoked by serotonin in rats (Pharmacology and Toxicology, 70, Supp II, 17-22 (1992)).
It is known that 5HT3 receptor antagonists slow colonic transit and may even cause mild constipation. (Aliment. Pharmacol. Therap. (1990), 4, 139-144; Digestive Diseases and Sciences, vol 35, 4, 477-480). Hence it was quite surprising to find that 5HT3 antagonists have a synergistic effect with osmotic agents to obtain intestinal lavage, i.e. an induced form of diarrhea which is quite the opposite of constipation.
Interesting 5HT3 antagonists are Azasetron HC1, Granisetron HC1, Ondansetron HC1, Tropisetron, DAT-582, Dolasetron mesylate, Itasetron, N-3389, Pancopride,
Ramosetron HC1, RG-12915, (R)-Zacopride, Lurosetron, E-3620, GK-128, KB-6933, KF-20170, and SL-90.0539.
An equally interesting 5HT3 antagonist is (-)-cis-4-amino-5-chloro-2,3-dihydro-N-[l- [3-[(3,4-dihydro-4-oxo-2-pyrimidinyl)amino]propyl]-3-methoxy-4-piperidinyl]-2,2-di- methyl-7-benzofurancarboxamide, which will be referred to hereinafter as "COMPOUND A", which is described as compound number 1 of WO 94/12494, published 9 June 1994.
Of course the pharmaceutically acceptable acid or base addition salt of the 5HT3 antagonists are also intended to be included in the present invention. The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the 5HT3 antagonists are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
The 5HT3 antagonists containing an acidic proton may also be converted into their non- toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.
Laxatives
Laxatives are drugs that promote defecation. Precise mechanisms of action of many laxatives remain uncertain because of the complex factors that affect colonic function, prominent variations of water and electrolyte transport among experimental species and preparations, and a certain costiveness of research in this area. Three general mechanisms of laxative action can be described. (1) By their hydrophilic or osmotic properties, laxatives may cause retention of fluid in colonic contents, thereby increasing bulk and softness and facilitating transit. (2) Laxatives may act, both directly and indirectly, on the colonic mucosa to decrease net absorption of water and ΝaCl. (3) Laxatives may increase intestinal motility, causing decreased absorption of salt and water secondary to decreased transit time. Mostly one recognizes three major classes of laxatives, i.e. 1) dietary fiber and bulk-forming laxatives, 2) saline and osmotic laxatives and 3) stimulant laxatives, (see Goodman and Gilman, seventh edition, pp 994 to 1003).
The bulk-forming laxatives include a wide range of natural and semisynthetic polysaccharides and cellular derivatives that are only partially digested. The undigested portions are hydrophilic and swell in the presence of water to form a viscous solution or gel. The increased intraluminal pressure reflexively stimulates peristalsis, diminishes colonic transit time and produces a soft gelatinous stool (" Remington's Pharmaceutical Sciences", page 783 - 786, 1990, Mack Publishing Company, Easton, Pennsylvania, 18th edition).
The stimulant laxatives act on the intestinal tract to increase its motor activity. The more commonly employed agents are the anthraquinone laxatives, such as, e.g. cascara sagrada and senna; the diphenylmethane derivatives, such as, e.g. phenolphtalein and bisacodyl; and castor oil ("Remington's Pharmaceutical Sciences", page 783 - 786, 1990, Mack Publishing Company, Easton, Pennsylvania, 18th edition).
Saline and osmotic laxatives are the primary class of laxatives envisaged in this invention.
Saline and osmotic laxatives include various magnesium salts; the sulfate, phosphate, and tartrate salts of sodium and potassium; the dissacharide lactulose; glycerin; and sorbitol. They are poorly and slowly absorbed and act by their osmotic properties in the luminal fluid.
Two examples of these osmotic agents which are commercially available for intestinal cleansing are KleanPrep® and GoLytely®.
The present invention is concerned with the use of a 5HT3 antagonist for the manufacture of a medicament that will improve, accelerate or promote the intestinal cleansing by laxatives, in particular osmotic agents. Hence, a method of treatment is claimed whereby an effective amount of a 5HT3 antagonist is administered to a warm- blooded animal, in particular a mammal, in combination with a laxative, in particular an osmotic agent.
The terms "accelerating", "improving", or "promoting" are used as synonyms throughout this text.
The patients envisaged in this treatment are people whose bowel needs to be cleaned prior to diagnostic or surgical procedures. Another group of patients are those patients who are to be prevented from straining at the stool, these patients include people suffering from hernia or cardiovascular disease. In addition, the combination of the present invention can be indicated, both before and after surgery, to maintain soft feces in patients with hemorrhoids and other anorectal disorders.
Osmotic agents at cathartic doses are frequently employed prior to radiological examination of the gastrointestinal tract, kidneys, or other abdominal or retroperitoneal structures and prior to elective bowel surgery. Hence, also for these applications the presently described combination may be useful.
Furthermore the combination of the present invention can also be used in the treatment of drug overdosage and poisoning, by removing agents from the intestine. The combination of the present invention may also be employed in further combination with with certain anthelmintics.
As is demonstrated in the experimental part the present invention provides a method to accelerate and/or enforce the action of laxatives, especially osmotic agents. The laxatives can be administered or co-administered orally or rectally. Also provided is a method of accelerating intestinal lavage in a warm-blooded animal, in particular a mammal, by administration of a laxative in combination with an effective amount of a
5HT3-antagonist.
In general, "co-administration" means that the laxative and the 5HT3~antagonist are present in the gastro-intestinal tract during at least partially overlapping times. Additionally, "co-administration" comprehends administering more than one dose of said laxative within 1 hour after a dose of the 5HT3-antagonist, in other words, the 5HT3-antagonist need not be administered again before or with every administration of said laxative, but may be administered intermittently during the course of treatment.
The present invention is also concerned with the use of said 5HT3 antagonists in combination with a laxative for the treatment of constipation, such as acute constipation, chronic constipation or refractory constipation. Consequently, a method is provided to treat constipation, such as, e.g. acute constipation, chronic constipation or refractory constipation, in warm-blooded animals, in particular mammals, by administration of a laxative in combination with an effective amount of a 5HT3 antagonist.
The 5HT3-antagonists may be formulated into various pharmaceutical forms for administration purposes. To prepare these pharmaceutical compositions, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is intimately mixed with a pharmaceutically acceptable carrier. Said carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection.
For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are _ obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on. as an ointment. Acid addition salts of the compounds of formula (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
The dosages of the drugs used in the present invention must, in the final analysis, be set by the physician in charge of the case, using knowledge of the drugs, the properties of the drugs in combination as determined in clinical trials, and the characteristics of the patient, including diseases other than that for which the physician is treating the patient. In general it is contemplated that an effective amount of a 5HT3 antagonist would be from about 0.001 mg kg to about 50 mg/kg body weight, preferably from about 0.02 mg/kg to about 5 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.
As an additional feature of the invention, this invention provides a therapeutic package suitable for commercial sale, comprising a container, an dosage form of a 5HT3 antagonist and a laxative, in particular an osmotic agent. This laxative or osmotic agent is often in the form of a powder, which is normally to be dissolved or suspended in a certain amount of water. Consequently, the present invention also relates to a product comprising a 5HT3 antagonist and a laxative, in particular an osmotic agent, for simultaneous, separate or sequential use in the treatment of constipation or for promoting intestinal lavage, provided that said product does not contain an opioid antagonist. Such a product may comprise a kit comprising a container containing a pharmaceutical composition of a laxative, and another container comprising a pharmaceutical composition of the 5HT3 antagonist. The product with separate compositions of the laxative and the 5HT3 antagonist has the advantage that appropriate amounts of each component, and timing and sequence of administration can be selected in function of the patient.
The proviso is intended to exclude the combinations as disclosed in WO-96/14071. WO-96/14071, published on 17 May 1996, discloses combinations consisting of laxatives, α-adrenergic agents, antiemetic agents, gastric protectors, optionally proton pump inhibitors, anxiolytic compounds, an anesthetic sleep-inducing agent, and an opioid antagonist, such as nalaxone or naltrexone; intended to suppress dependence on opioids.
Experimental part Beagle dogs of both sexes and varying in body weight were used. During the experiments, the dogs were individually housed in cages. They were uniquely identified by an ear tattoo number (received at the time of weaning). The animals were fasted overnight but were given free access to fresh tap water via automatic drinking nipples in the back of the cage.
Binding affinity for the 5HT3 receptor
In vitro 5HT3 receptor binding was measured using NxG 108CC15 cells and [3H]GR 65630. Cells were homogenized in tris.HCl buffer (20mM, pH = 7.5) containing NaCl (154 mM); the final cell concentration corresponded to approximately 106 cell/ml. Incubation mixtures for radioligand binding assays were composed of 0.5 ml membrane suspensions, 0.025 ml [3H]GR 65630 (final concentration 2 nM), and 0.025 ml either solvent (10% dimethylsulf oxide) for total binding, or tropisetron (final concentration 1.0 μM) for non-specific binding, or drug solution. The incubation was run for 60 minutes at 37°C. Labelled membranes were collected and raised by rapid- filtration under suction over Walkman GF B plan fibre filters (presoaked in 0.1 % polyethyleneimine for at least 1 hour) using a 40-well filtration manifold. Test compounds were added at appropriate concentrations (60 minutes incubation time), in such a way that the inhibition curves were defined by at least eight to twelve concentration points, measured in duplicate. All experiments were repeated independently at least two times. Radioactivity on the filters was counted in a Packard Tri-carb 1600CA liquid scintillation analyzer. Counting data were collected directly in a Macintosh SE personal computer and further transferred to a Macintosh II personal computer. Counting data from assays in the presence of a compound were automatically expressed as percent of total binding measured in the absence of test compound. Inhibition curves plotting percent of total binding versus the log concentrations of the test compound were automatically generated. The sigmoidal inhibition curves were analyzed by computerized curve-fitting, with a programme using non-linear regression analysis for one- or two site curve fitting (modifications of equations described in Oestreicher E.G. and Pinto G.F., Comput. Biol. Med., 17, 53-68 (1987). The -log IC5o values (PIC50', IC50 defined as the concentration producing 50% inhibition of specific radioligand binding) were derived from individual curves. Kj values were calculated according to the method of Cheng and Prusoff (Cheng Y.C. and Prusoff W.H., Biochem. Pharmacol., 22, 3099-3108, 1973)[K; = IC50/(1 + C/KD)] using the KD (1.7 nM) and the concentration (C) of the radiolabelled [3H]GR 65630 (2 nM). The Kj values of the test compounds are presented as logarithmic mean and corresponding 95% confidence limits of the various determinations; and are presented in Table 1 in the column labelled "5HT3 receptor K; (95% c.l.) nM".
Study 1 : MgSO4 induced intestinal lavage
Beagle dogs (of both sexes and varying in body weight, 16 hours deprived from food) were orally pretreated with the test compound (0.5 ml/kg) and challenged 1 hour later with an oral administration of magnesium sulphate (MgSO 7H2θ, 64g/l, 0.26M; 200 ml). The onset of MgSO4-induced intestinal lavage was assessed over a period of 4 hours after challenge. Liquid stools within 4 hours occured almost never in control animals treated with distilled water (3.0% false positives; n>100) and were considered to reflect significant acceleration of the MgSOAnduced intestinal lavage. Doses in the active dose range were given to five animals each, tested in separate experimental sessions including solvent-treated control animals. All-or-none criteria, based on the distribution of the results obtained in a large number of solvent-treated animals, were used to calculate EDso-values and 95% confidence limits (c.l.) according to Finney's iterative method (Finney D.J., "Probit analysis", Cambridge University Press, 1962).
Test compounds :
The following test compounds were obtained from the companies of origin : bemesetron, BIMU-8, DAU-6236, granisetron, ondansetron, tropisetron, YM-060, renzapride and zacopride, as well as Compound A.
Figure imgf000011_0001
Results :
The active doses or concentrations of the test compounds have been listed in Table 1. All compounds showed affinity for the 5HT3 receptor, inhibited 5-hydroxykynuramine (5-OH-K)-induced contractions of the guinea-pig ileum, antagonized the Von Bezold Jarisch reflex and stimulated gastric emptying in rats, and the accelerated appearance of MgSO4-induced loose stools in dogs.
Table 1 : Binding to the serotonin 5HT3 receptor (Kj, nM); and acceleration of MgSO4 induced diarrhea in dogs (ED50, μg/kg, po).
Figure imgf000012_0001
Study 2 : KleanPrep®-induced intestinal lavage
The dogs were orally pretreated with test compound or distilled water (0.5 ml/kg) and 1 hour later challenged by gavage with KleanPrep® solution. Dependent on the type of experiment, the KleanPrep® solution was administered more than once at 15 minutes intervals. The standard administration volume was 200 ml. The occurrence of liquid stools at 1, 2, 3, 4, 5 and 6 hours after the first administration of KleanPrep® was noted. The KleanPrep® solution consisted of polyethyleneglycol 3350 (59 g/1), sodium sulfate (5.685 g/1), sodium hydrogencarbonate (1.685 g/1), sodium chloride (1.465 g/1), potassium chloride (0.7425 g/1), aspartate (0.0494 g/1) and vanille (0.3291 g/1).
Each dose of the test compounds was given to 5 animals. All-or-none criteria were used to calculate EDsn-values and 95% confidence limits according to the iterative method of Finney (Finney, D.J., "Probit analysis", Cambridge University Press, 1962). In a first experiment, five dogs were treated at 15 minutes intervals with 200 ml KleanPrep® until the occurrence of the first liquid stool. During the process of KleanPrep® administration, the abdomen of the dogs gradually distended as a consequence of the steadily increasing administered volume of KleanPrep® and the dogs started to urinate. Two dogs produced the first liquid stool after the 7th administration of KleanPrep® (corresponding to a total volume of 1400 ml; the first liquid stool at 95 and 101 min). A third dog displayed the first liquid stool after 9 administrations (1800 ml KleanPrep®; the first liquid stool at 124 min). The other two dogs vomited just after the 14th KleanPrep® administration (as much as 2800 ml KleanPrep®), after which further administration was stopped; they displayed the first liquid stool at 21 1 and 305 minutes after the start of the KleanPrep® administration.
In a second experiment, the occurrence of liquid stools was determined at several time intervals after single administration of 200 ml KleanPrep® in dogs pretreated one hour earlier with water (0.5 ml/kg, p.o.) or "COMPOUND A" (0.16 mg/kg, p.o.). None of the five dogs pretreated with water displayed liquid stools during a 4 hour observation period starting after the KleanPrep® administration. In contrast, three out of five dogs treated with "COMPOUND A" displayed liquid stools within 2 hours after KleanPrep® administration.
In a third experiment, the occurrence of liquid stools was determined at several time intervals after four administrations of KleanPrep® (4 x 200 ml at 15 minute intervals) in dogs pretreated one hour earlier with water (0.5 ml/kg, p.o.) or "COMPOUND A"
(0.16 mg/kg, p.o.). Even at the end of the 6 hour observation period, only one out of five dogs pretreated with water had produced liquid stools (onset at 255 minutes after the first administration of KleanPrep®. On the other hand, all five dogs pretreated with
"COMPOUND A" displayed their first liquid stool within 2 hours (at 38, 39, 42, 52, and 77 minutes) after the first administration of KleanPrep®.
In a fourth experiment, the occurrence of liquid stools was determined at several time intervals after two administrations of KleanPrep® (2 x 200 ml) in dogs pretreated one hour earlier with water (0.5 ml/kg, p.o.) or several doses of "COMPOUND A". In twenty five controls animals pretreated with water (0.5 ml/kg, p.o.), liquid stools remained absent up to 6 hours after the first administration of KleanPrep®. After oral pretreatment with "COMPOUND A", however, liquid stools were already observed within 4 hours (ED50: 0.0036 mg/kg). Higher doses of "COMPOUND A" were able to further accelerate the occurrence of liquid stools to within 3 hours (dose increment : 1.1 times), 2 hours (dose increment : 3 times), and even 1 hour after KleanPrep® (dose increment: 24 times; ED50: 0.085 mg/kg). According to the responsible technician, furthermore, it was conspicuous that urination was observed in all control animals but never in animals pretreated with effective doses of "COMPOUND A".
The present results confirm that "COMPOUND A" and other 5HT3 antagonists as well act synergistically with orally administered osmotic agents to induce liquid stools in dogs.

Claims

Claims
1. Use of a 5HT3 antagonist for the manufacture of a medicament for accelerating intestinal lavage in combination with a laxative.
2. Use of a 5HT3 antagonist for the manufacture of a medicament for treating constipation in combination with a laxative.
3. Use according to claim 1 or 2 wherein the 5HT3 antagonist is selected from the group consisting of Azasetron, Granisetron, Ondansetron, Tropisetron, DAT-582,
Dolasetron, Itasetron, N-3389, Pancopride, Ramosetron, RG-12915, (R)-Zacopride, Lurosetron, E-3620, GK-128, KB-6933, KF-20170, SL-90.0539 and (-)-cis-4- amino-5-chloro-2,3-dihydro-N-[l-[3-[(3,4-dihydro-4-oxo-2-pyrimidinyl)amino]- propyl]-3-methoxy-4-piperidinyl]-2,2-dimethyl-7-benzofurancarboxamide and the pharmaceutically acceptable acid addition salts thereof.
4. Use according to claims 1 to 3 wherein the laxative is an osmotic agent.
5. Use according to claims 1 to 3 wherein the laxative is a polyethylene glycol (PEG)-electrolyte solution.
6. Use according to any of claims 1 to 5 wherein the laxative and the 5HT3 antagonist are each administered in separate oral dosage forms.
7. Use according to any of claims 1 to 5 wherein the laxative and the 5HT3 antagonist are administered together in a combination oral dosage form.
8. A product comprising a 5HT3 antagonist and an osmotic agent for simultaneous, separate or sequential use in the treatment of constipation or for accelerating intestinal lavage, provided that said product does not contain an opioid antagonist.
9. A method of accelerating intestinal lavage in a mammal by administration of a laxative in combination with an effective amount of a 5HT3 antagonist.
10. A method for treating constipation in a mammal by administration of a laxative in combination with an effective amount of a 5HT3 antagonist.
PCT/EP1998/002356 1997-04-18 1998-04-14 Use of 5ht3 antagonists for promoting intestinal lavage WO1998047481A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US09/403,248 US6235745B1 (en) 1997-04-18 1998-04-14 Use of 5HT3, antagonists for promoting intestinal lavage
EP98922759A EP0975327B1 (en) 1997-04-18 1998-04-14 Use of 5ht3 antagonists for promoting intestinal lavage
KR10-1999-7007936A KR100529512B1 (en) 1997-04-18 1998-04-14 Use of 5HT3 antagonists for promoting intestinal lavage
JP54502298A JP2001523239A (en) 1997-04-18 1998-04-14 Use of 5HT (3) antagonists to promote intestinal lavage
DE69816060T DE69816060T2 (en) 1997-04-18 1998-04-14 USE OF 5HT3 ANTAGONISTS TO PROMOTE THE COLON
DK98922759T DK0975327T3 (en) 1997-04-18 1998-04-14 Use of 5HT3 antagonists to promote intestinal lavage
AU75282/98A AU745361B2 (en) 1997-04-18 1998-04-14 Use of 5HT3 antagonists for promoting intestinal lavage
CA002286076A CA2286076C (en) 1997-04-18 1998-04-14 Use of 5ht3 antagonists for promoting intestinal lavage
AT98922759T ATE243993T1 (en) 1997-04-18 1998-04-14 USE OF 5HT3 ANTAGONISTS TO PROMOTE INTESTINAL FLUSHMENT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201149.8 1997-04-18
EP97201149 1997-04-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/403,248 A-371-Of-International US6235745B1 (en) 1997-04-18 1998-04-14 Use of 5HT3, antagonists for promoting intestinal lavage
US09/801,978 Division US6555546B2 (en) 1997-04-18 2001-03-08 Use of 5HT3 antagonists for promoting intestinal lavage

Publications (1)

Publication Number Publication Date
WO1998047481A1 true WO1998047481A1 (en) 1998-10-29

Family

ID=8228223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/002356 WO1998047481A1 (en) 1997-04-18 1998-04-14 Use of 5ht3 antagonists for promoting intestinal lavage

Country Status (12)

Country Link
US (2) US6235745B1 (en)
EP (1) EP0975327B1 (en)
JP (1) JP2001523239A (en)
KR (1) KR100529512B1 (en)
AT (1) ATE243993T1 (en)
AU (1) AU745361B2 (en)
CA (1) CA2286076C (en)
DE (1) DE69816060T2 (en)
DK (1) DK0975327T3 (en)
ES (1) ES2202855T3 (en)
PT (1) PT975327E (en)
WO (1) WO1998047481A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
WO2002041918A2 (en) * 2000-11-24 2002-05-30 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
WO2002085901A1 (en) * 2001-04-19 2002-10-31 Pharmacia & Upjohn Company Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)
WO2007019888A2 (en) * 2005-08-12 2007-02-22 Ctg Pharma S.R.L. Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
US10342848B2 (en) 2013-02-25 2019-07-09 Bausch Health Ireland Limited Agonists of guanylate cyclase and their uses
WO2020067456A1 (en) * 2018-09-28 2020-04-02 武田薬品工業株式会社 Heterocyclic compound

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6946149B2 (en) * 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
AU2003272740A1 (en) * 2002-10-01 2004-04-23 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
US6996500B2 (en) * 2002-10-30 2006-02-07 Hewlett-Packard Development Company, L.P. Method for communicating diagnostic data
EP1558081A4 (en) * 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
EP1567163B1 (en) * 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Method of treating nausea, vomiting, retching or any combination thereof
JP2006522144A (en) 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド Treatment of lower urinary tract disorders
US7049319B2 (en) * 2003-09-23 2006-05-23 Semaan Abboud Colon cleansing composition and method
EP1736156A4 (en) * 2004-04-15 2010-06-16 Eisai R&D Man Co Ltd STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1 OCT-3-YL -2-¬1-METHYLBUT-2-YNYLOXY -BENZAMIDE CONTAINING COMPOSITION
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
CN101242820A (en) * 2005-08-16 2008-08-13 辛塔制药公司 Bis(thio-hydrazide amide) formulation
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
US7863271B2 (en) * 2006-08-07 2011-01-04 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5HT3 modulators
RS59667B1 (en) 2013-03-15 2020-01-31 Braintree Laboratories Inc Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB893267A (en) * 1958-11-25 1962-04-04 Sterling Drug Inc Laxative enemas
WO1994012494A1 (en) * 1992-11-20 1994-06-09 Janssen Pharmaceutica N.V. Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists
WO1996014071A1 (en) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combination of chemical compounds used as a medicament intended to suppress the dependence of individuals to opioids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US6103734A (en) 1994-11-04 2000-08-15 Legarda Ibanez; Juan Jose Drug combination as a medicament to suppress the dependence of individuals to opiates
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB893267A (en) * 1958-11-25 1962-04-04 Sterling Drug Inc Laxative enemas
WO1994012494A1 (en) * 1992-11-20 1994-06-09 Janssen Pharmaceutica N.V. Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists
WO1996014071A1 (en) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combination of chemical compounds used as a medicament intended to suppress the dependence of individuals to opioids

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Martindale The Extra Pharmacopoeia", 1989, THE PHARMACEUTICAL PRESS, LONDON, GB, XP002040773 *
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY, EASTON, PENNSYLVANIA, XP002040774 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; F. S. F. TAM ET AL: "Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle", XP002040777 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; J. W. UPWARD ET AL: "The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist", XP002040776 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; S. GORE ET AL: "Colonic Transit in man is slowed by ondasetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist", XP002040775 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
WO2001026657A1 (en) * 1999-10-08 2001-04-19 Sanofi-Synthelabo Use of (r)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
WO2002041918A2 (en) * 2000-11-24 2002-05-30 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
WO2002041918A3 (en) * 2000-11-24 2002-07-11 Janssen Pharmaceutica Nv Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
WO2002085901A1 (en) * 2001-04-19 2002-10-31 Pharmacia & Upjohn Company Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)
US6869946B2 (en) 2001-04-19 2005-03-22 Pfizer Inc Substituted azabicyclic moieties for the treatment of disease
WO2007019888A2 (en) * 2005-08-12 2007-02-22 Ctg Pharma S.R.L. Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
WO2007019888A3 (en) * 2005-08-12 2007-07-12 Ctg Pharma S R L Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
US10342848B2 (en) 2013-02-25 2019-07-09 Bausch Health Ireland Limited Agonists of guanylate cyclase and their uses
US10967043B2 (en) 2013-02-25 2021-04-06 Bausch Health Ireland Limited Agonists of guanylate cyclase and their uses
WO2020067456A1 (en) * 2018-09-28 2020-04-02 武田薬品工業株式会社 Heterocyclic compound
US11970483B2 (en) 2018-09-28 2024-04-30 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
EP0975327B1 (en) 2003-07-02
KR20000075858A (en) 2000-12-26
DE69816060D1 (en) 2003-08-07
AU745361B2 (en) 2002-03-21
ATE243993T1 (en) 2003-07-15
US20010020025A1 (en) 2001-09-06
JP2001523239A (en) 2001-11-20
ES2202855T3 (en) 2004-04-01
AU7528298A (en) 1998-11-13
CA2286076A1 (en) 1998-10-29
CA2286076C (en) 2006-12-12
US6235745B1 (en) 2001-05-22
KR100529512B1 (en) 2005-11-22
DE69816060T2 (en) 2004-04-22
EP0975327A1 (en) 2000-02-02
PT975327E (en) 2003-11-28
DK0975327T3 (en) 2003-10-20
US6555546B2 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
EP0975327B1 (en) Use of 5ht3 antagonists for promoting intestinal lavage
CA2814523C (en) Colonic purgative composition with soluble binding agent
Madersbacher et al. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride
US6482837B1 (en) Antimuscarinic compounds and methods for treatment of bladder diseases
KR20010015707A (en) Medicaments
Shoaib et al. Antagonism of stimulus properties of nicotine by dihydro-β-erythroidine (DHβE) in rats
US20040096423A1 (en) Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage
US4904673A (en) Agent for treating bradycardia and bradyarrhythmia
CN1444479A (en) Medicaments containing cilansetron for treating non-obstipated male IBS patients
Hall Non-specific drug therapy
AU2012202628B2 (en) Colonic purgative composition with soluble binding agent
CN104138599A (en) Application of medicinal composition
DE3820347A1 (en) USE OF 11-SUBSTITUTED 5,11-DIHYDRO-6H-PYRIDO (2,3-B) (1,4) BENZODIAZEPIN-6-ONEN FOR THE TREATMENT OF BRADYCARDIES AND BRADYARRHYTHMIES IN THE HUMAN AND VETERINARY MEDICINE
MXPA00003375A (en) Medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998922759

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019997007936

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 545022

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2286076

Country of ref document: CA

Ref country code: CA

Ref document number: 2286076

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09403248

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 75282/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998922759

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997007936

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 75282/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998922759

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019997007936

Country of ref document: KR